Suppr超能文献

肾细胞癌术前全身治疗的手术并发症:一项系统评价

Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review.

作者信息

McCormick Barrett, Meissner Matthew A, Karam Jose A, Wood Christopher G

机构信息

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Kidney Cancer. 2017 Nov 27;1(2):115-121. doi: 10.3233/KCA-170016.

Abstract

BACKGROUND

Locally advanced and metastatic renal cell carcinoma (RCC) is associated with poor survival outcomes. The integration of presurgical systemic therapy with targeted molecular agents prior to surgical resection of RCC tumors has been utilized to improve on these outcomes. These agents may be associated with an increased risk of perioperative complications due to their action on angiogenesis and cell proliferation.

OBJECTIVE

To examine the evidence for the incidence and severity of perioperative complications following presurgical targeted therapy for locally advanced or metastatic RCC.

METHODS

We performed a systematic review of retrospective studies, prospective clinical trials, and meta-analyses using key search terms in PubMed and Medline. Studies were screened for eligibility and data were extracted by the authors. A qualitative analysis was performed and the complications for available targeted agents was reported.

RESULTS

Retrospective analyses and small prospective trials indicate varying complication rates and types based on presurgical therapies. While some studies indicate a possible increase in wound-related complications, other studies did not show similar results. Additional unique complications reported include an increase in surgical adhesions. There was not any significant difference in overall or bleeding complications.

CONCLUSIONS

Overall, these studies demonstrate an acceptable level of surgical complications that should not discourage the clinician considering presurgical therapy. The results of pending trials looking at presurgical therapies will provide further information.

摘要

背景

局部晚期和转移性肾细胞癌(RCC)的生存结局较差。在对RCC肿瘤进行手术切除之前,将术前全身治疗与靶向分子药物相结合已被用于改善这些结局。由于这些药物对血管生成和细胞增殖的作用,它们可能与围手术期并发症风险增加有关。

目的

研究术前靶向治疗局部晚期或转移性RCC后围手术期并发症的发生率和严重程度的证据。

方法

我们使用PubMed和Medline中的关键检索词对回顾性研究、前瞻性临床试验和荟萃分析进行了系统评价。筛选符合条件的研究,作者提取数据。进行定性分析并报告可用靶向药物的并发症。

结果

回顾性分析和小型前瞻性试验表明,根据术前治疗的不同,并发症发生率和类型也有所不同。虽然一些研究表明与伤口相关的并发症可能增加,但其他研究并未显示出类似结果。报告的其他独特并发症包括手术粘连增加。总体或出血并发症方面没有显著差异。

结论

总体而言,这些研究表明手术并发症处于可接受水平,不应阻碍临床医生考虑术前治疗。正在进行的术前治疗试验结果将提供更多信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/947c/6179118/18e2f3529f53/kca-1-kca170016-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验